4D Molecular Therapeutics (FDMT) CFO awarded 480,000-share stock option grant

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. reported an insider equity award for its Chief Financial Officer, Kristian Humer. The filing shows a grant of a stock option (right to buy) covering 480,000 shares of common stock at an exercise price of $10.51 per share on 12/09/2025, with an expiration date of 12/08/2035.

According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of November 17, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. The option becomes fully vested on the fourth anniversary of the vesting commencement date, as long as the grantee continues as a service provider to the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Humer Kristian

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.51	12/09/2025		A		480,000		(1)	12/08/2035	Common Stock	480,000	$0	480,000	D

Explanation of Responses:

1. 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily as Attorney-in-Fact for Kristian Humer	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 4D Molecular Therapeutics (FDMT) report in this filing?

The filing reports the grant of a stock option to the Chief Financial Officer, covering 480,000 shares of 4D Molecular Therapeutics, Inc. common stock.

What is the exercise price and expiry of the FDMT CFO stock option grant?

The stock option has an exercise price of $10.51 per share and an expiration date of 12/08/2035, as disclosed in the filing.

How does the stock option granted to the FDMT CFO vest?

The filing states that 25% of the option vests on the first anniversary of November 17, 2025, with the remaining shares vesting in 36 equal monthly installments so that it is fully vested on the fourth anniversary, while the grantee remains a service provider.

Who is the reporting person in this FDMT Form 4 and what is their role?

The reporting person is Kristian Humer, who is identified as an Officer of 4D Molecular Therapeutics, Inc., with the title Chief Financial Officer.

How many derivative securities does the FDMT CFO beneficially own after this transaction?

After the reported transaction, the filing shows beneficial ownership of 480,000 derivative securities (stock options), held with direct ownership.

Was this FDMT insider transaction reported as an acquisition or a disposition?

The transaction is coded as "A" in the filing, indicating an acquisition of derivative securities (a stock option grant) rather than a sale.